Enoxaparin dosing for venous thromboembolism prophylaxis in hospitalized underweight adult patients: a retrospective cohort study
<h3>Background</h3><p dir="ltr">Enoxaparin is commonly used for venous thromboembolism (VTE) prophylaxis in adult hospitalized patients. Although anti-Xa levels are inversely related to body weight, limited studies evaluated clinical outcomes of dose reduction in the unde...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , |
| منشور في: |
2025
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513534577082368 |
|---|---|
| author | Salam Ibrahim Abou Safrah (21264303) |
| author2 | Mohamed Omar Saad (12535545) May Alasmar (19744495) Fatima Ashfaq Butt (21264306) Somaya Khaled Koraysh (21264309) |
| author2_role | author author author author |
| author_facet | Salam Ibrahim Abou Safrah (21264303) Mohamed Omar Saad (12535545) May Alasmar (19744495) Fatima Ashfaq Butt (21264306) Somaya Khaled Koraysh (21264309) |
| author_role | author |
| dc.creator.none.fl_str_mv | Salam Ibrahim Abou Safrah (21264303) Mohamed Omar Saad (12535545) May Alasmar (19744495) Fatima Ashfaq Butt (21264306) Somaya Khaled Koraysh (21264309) |
| dc.date.none.fl_str_mv | 2025-05-07T03:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1186/s12959-025-00716-w |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Enoxaparin_dosing_for_venous_thromboembolism_prophylaxis_in_hospitalized_underweight_adult_patients_a_retrospective_cohort_study/30405592 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Pharmacology and pharmaceutical sciences Enoxaparin Dose Prophylaxis Venous thromboembolism Deep vein thrombosis Body mass index Weight |
| dc.title.none.fl_str_mv | Enoxaparin dosing for venous thromboembolism prophylaxis in hospitalized underweight adult patients: a retrospective cohort study |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Background</h3><p dir="ltr">Enoxaparin is commonly used for venous thromboembolism (VTE) prophylaxis in adult hospitalized patients. Although anti-Xa levels are inversely related to body weight, limited studies evaluated clinical outcomes of dose reduction in the underweight population.</p><h3>Objective</h3><p dir="ltr">To compare the incidence of bleeding and VTE in underweight patients receiving reduced doses of enoxaparin (< 40 mg daily) versus the standard dose (40 mg daily) for VTE prophylaxis.</p><h3>Methods</h3><p dir="ltr">This was a multicentre retrospective cohort study at Hamad Medical Corporation in Qatar. We included hospitalized patients with a total body weight ≤ 57 kg or body mass index (BMI) ≤ 18.5 kg/m<sup>2</sup> who received prophylactic enoxaparin for at least 48 h. The outcomes were bleeding, VTE, and composite unfavourable outcome (bleeding or VTE). Inverse-probability-of-treatment weighting (IPTW) was used to adjust for confounding.</p><h3>Results</h3><p dir="ltr">We identified 1,130 eligible patients, of whom 124 patients (11%) received the reduced dose, and 1,006 patients (89%) received the standard dose. Bleeding occurred in one patient (0.8%) of the reduced dose group compared to 15 patients (1.5%) in the standard dose group (<i>p</i> > 0.99), VTE occurred in two patients (1.6%) in the reduced dose group compared to four patients (0.4%) in the standard dose group (<i>p</i> = 0.13). In the IPTW analysis, there was no significant difference in overall bleeding (odds ratio (OR) 1.4, 95% CI 0.18–10.75, <i>p</i> = 0.74), VTE (OR 0.3, 95% CI 0.05–1.81, <i>p</i> = 0.19), or the composite unfavourable outcome (OR 0.74, 95% CI 0.2–2.75, <i>p</i> = 0.66).</p><h3>Conclusion</h3><p dir="ltr">There is no significant difference in the incidence of bleeding or VTE between the reduced dose and the standard dose of enoxaparin for VTE prophylaxis in underweight adult patients. Due to the low event rates in both groups, larger studies are required to delineate any differences between the two dosing strategies.</p><h2>Other Information</h2><p dir="ltr">Published in: Thrombosis Journal<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1186/s12959-025-00716-w" target="_blank">https://dx.doi.org/10.1186/s12959-025-00716-w</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_9fd7f9b535c9fb8b2167c7b29c3a6b99 |
| identifier_str_mv | 10.1186/s12959-025-00716-w |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/30405592 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Enoxaparin dosing for venous thromboembolism prophylaxis in hospitalized underweight adult patients: a retrospective cohort studySalam Ibrahim Abou Safrah (21264303)Mohamed Omar Saad (12535545)May Alasmar (19744495)Fatima Ashfaq Butt (21264306)Somaya Khaled Koraysh (21264309)Biomedical and clinical sciencesPharmacology and pharmaceutical sciencesEnoxaparinDoseProphylaxisVenous thromboembolismDeep vein thrombosisBody mass indexWeight<h3>Background</h3><p dir="ltr">Enoxaparin is commonly used for venous thromboembolism (VTE) prophylaxis in adult hospitalized patients. Although anti-Xa levels are inversely related to body weight, limited studies evaluated clinical outcomes of dose reduction in the underweight population.</p><h3>Objective</h3><p dir="ltr">To compare the incidence of bleeding and VTE in underweight patients receiving reduced doses of enoxaparin (< 40 mg daily) versus the standard dose (40 mg daily) for VTE prophylaxis.</p><h3>Methods</h3><p dir="ltr">This was a multicentre retrospective cohort study at Hamad Medical Corporation in Qatar. We included hospitalized patients with a total body weight ≤ 57 kg or body mass index (BMI) ≤ 18.5 kg/m<sup>2</sup> who received prophylactic enoxaparin for at least 48 h. The outcomes were bleeding, VTE, and composite unfavourable outcome (bleeding or VTE). Inverse-probability-of-treatment weighting (IPTW) was used to adjust for confounding.</p><h3>Results</h3><p dir="ltr">We identified 1,130 eligible patients, of whom 124 patients (11%) received the reduced dose, and 1,006 patients (89%) received the standard dose. Bleeding occurred in one patient (0.8%) of the reduced dose group compared to 15 patients (1.5%) in the standard dose group (<i>p</i> > 0.99), VTE occurred in two patients (1.6%) in the reduced dose group compared to four patients (0.4%) in the standard dose group (<i>p</i> = 0.13). In the IPTW analysis, there was no significant difference in overall bleeding (odds ratio (OR) 1.4, 95% CI 0.18–10.75, <i>p</i> = 0.74), VTE (OR 0.3, 95% CI 0.05–1.81, <i>p</i> = 0.19), or the composite unfavourable outcome (OR 0.74, 95% CI 0.2–2.75, <i>p</i> = 0.66).</p><h3>Conclusion</h3><p dir="ltr">There is no significant difference in the incidence of bleeding or VTE between the reduced dose and the standard dose of enoxaparin for VTE prophylaxis in underweight adult patients. Due to the low event rates in both groups, larger studies are required to delineate any differences between the two dosing strategies.</p><h2>Other Information</h2><p dir="ltr">Published in: Thrombosis Journal<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1186/s12959-025-00716-w" target="_blank">https://dx.doi.org/10.1186/s12959-025-00716-w</a></p>2025-05-07T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1186/s12959-025-00716-whttps://figshare.com/articles/journal_contribution/Enoxaparin_dosing_for_venous_thromboembolism_prophylaxis_in_hospitalized_underweight_adult_patients_a_retrospective_cohort_study/30405592CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/304055922025-05-07T03:00:00Z |
| spellingShingle | Enoxaparin dosing for venous thromboembolism prophylaxis in hospitalized underweight adult patients: a retrospective cohort study Salam Ibrahim Abou Safrah (21264303) Biomedical and clinical sciences Pharmacology and pharmaceutical sciences Enoxaparin Dose Prophylaxis Venous thromboembolism Deep vein thrombosis Body mass index Weight |
| status_str | publishedVersion |
| title | Enoxaparin dosing for venous thromboembolism prophylaxis in hospitalized underweight adult patients: a retrospective cohort study |
| title_full | Enoxaparin dosing for venous thromboembolism prophylaxis in hospitalized underweight adult patients: a retrospective cohort study |
| title_fullStr | Enoxaparin dosing for venous thromboembolism prophylaxis in hospitalized underweight adult patients: a retrospective cohort study |
| title_full_unstemmed | Enoxaparin dosing for venous thromboembolism prophylaxis in hospitalized underweight adult patients: a retrospective cohort study |
| title_short | Enoxaparin dosing for venous thromboembolism prophylaxis in hospitalized underweight adult patients: a retrospective cohort study |
| title_sort | Enoxaparin dosing for venous thromboembolism prophylaxis in hospitalized underweight adult patients: a retrospective cohort study |
| topic | Biomedical and clinical sciences Pharmacology and pharmaceutical sciences Enoxaparin Dose Prophylaxis Venous thromboembolism Deep vein thrombosis Body mass index Weight |